Navigation Links
Vaccine blocks malaria transmission in lab experiments
Date:7/22/2009

Researchers at the Johns Hopkins Malaria Research Institute have for the first time produced a malarial protein (Pfs48/45) in the proper conformation and quantity to generate a significant immune response in mice and non-human primates for use in a potential transmission-blocking vaccine. Antibodies induced by Pfs48/45 protein vaccine effectively blocked the sexual development of the malaria-causing parasite, Plasmodium, as it grows within the mosquito. Sexual development is a critical step in the parasite's life cycle and necessary for continued transmission of malaria from mosquitoes to humans. The study is published in the July 22 edition of the journal PLoS ONE.

"Development of a successful transmission-blocking vaccine is an essential step in efforts to control the global spread of malaria. In our study, we demonstrate the relative ease of expression and induction of potent transmission-blocking antibodies in mice and non-human primates. This approach provides a compelling rationale and basis for testing a transmission-blocking vaccine in humans," said Nirbhay Kumar, PhD, senior author of the study and professor in Johns Hopkins Bloomberg School of Public Health's W. Harry Feinstone Department of Molecular Microbiology and Immunology.

For the study, the research team expressed full-length Pfs48/45 in E. coli bacteria to produce the vaccine. Previous attempts to fully express the protein had not been successful. The vaccine was first given to mice in the laboratory. The vaccine was also tested in non-human primates (Olive baboons) in Kenya with similar results. According to the study, a single-dose vaccine provided a 93 percent transmission-blocking immune response, reaching greater than 98 percent after a booster given several months later.

"This is an exciting beginning to what might become an important tool in the arsenal for malaria control and progressive elimination of malaria transmission," said Kumar. There is no animal reservoir for human malaria and in that regard it is possible to gradually reduce malaria transmission to a point of almost eradication. However, Kumar cautioned that more research is needed to achieve that goal. For one, similar research efforts are needed to reduce transmission of Plasmodium vivax, another major human malaria parasite.

Malaria affects greater than 500 million people worldwide and is estimated to kill over one million people each year, most of whom are children living in Africa.


'/>"/>

Contact: Tim Parsons
tmparson@jhsph.edu
410-955-7619
Johns Hopkins University Bloomberg School of Public Health
Source:Eurekalert

Related biology news :

1. Penn-Wistar team gains insight into HIV vaccine failure
2. LSUHSCs Kolls awarded $1.8 million to improve vaccine strategies for P. carinii pneumonia
3. UTSA infectious disease researchers advancing vaccine against Valley fever
4. Targeting children effective use of limited supplies of flu vaccine and could help control flu spread
5. Preventing ear infections in the future: Delivering vaccine through the skin
6. Novel vaccine approach offers hope in fight against HIV
7. Princeton teams analysis of flu virus could lead to better vaccines
8. UTSA, Health Science Center collaborate with Merck & Co. to develop chlamydia vaccine
9. Novel lung cancer vaccine shows promise in fighting early-stage lung cancer
10. New evidence explains poor infant immune response to certain vaccines, says MU researcher
11. HPV vaccine may prevent preterm births
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2017)... WINSTON-SALEM, N.C. , Feb. 14, 2017  Wake ... FRY-shlog), M.D., as its new chief executive officer (CEO). ... succeeds CEO John D. McConnell , M.D., who ... new position at the Medical Center, after leading it ... oversee the full scope of Wake Forest Baptist,s academic ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2016. Revenue ... to $6.9 million in the same quarter last year. Operating ... compared to $2.6 million in the fourth quarter of 2015. ... million, or $0.02 per diluted share, which compares to $1.8 ...
Breaking Biology News(10 mins):
(Date:2/20/2017)... , ... February 20, 2017 , ... ... the re-launch of “Crosswalk Insight: Oncology™” (Crosswalk), a unique precision medicine knowledge visualization ... can now be accessed through Inspirata’s diagnostic cockpit and is downloadable as an ...
(Date:2/20/2017)... ... February 20, 2017 , ... PuraCath ... associated with peritoneal dialysis, announced today that it has published the result of ... in Peritoneal Dialysis International (PDI), the official Journal of the International Society ...
(Date:2/20/2017)...  Atrius Health and IBM (NYSE: IBM ... to develop a cloud based service designed to ... view of the multiple influences on an individual,s ... be designed to support shared decision making between ... nonprofit healthcare organization with 875 physicians caring for ...
(Date:2/18/2017)... ... February 17, 2017 , ... The BMT ... the Center for International Blood & Marrow Transplant Research (CIBMTR) will take place ... , The combined scientific sessions offer investigators, clinicians, laboratory technicians, clinical research ...
Breaking Biology Technology: